NEW YORK, April 28 (GenomeWeb News) - ChondroGene said yesterday that it will partner with Kaiser Permanente of Northern California on a prospective clinical study to evaluate its molecular diagnostic test for colon cancer.
The study will compare the results of the company's ColonSentry blood-based colon cancer test to colonoscopy findings in a group of 600 patients from at-risk and confirmed cancer populations.
The results of the study will be used to advance development of the test, ChondroGene said, and will "allow Kaiser Permanent to evaluate the test in a patient population."
Compared to current stool-based or endoscopic-based screening approaches, "a blood-based test would be more convenient and would likely enhance patient compliance," said T. R. Levin, director of colorectal cancer screening for the Kaiser Permanente Medical Group.
The ColonSentry test is the first commercial diagnostic application of ChondroGene's Sentinel Principle molecular diagnostic technology.